Tempus AI, Inc. (Nasdaq: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced that it has entered into a definitive agreement to acquire Personalis, Inc. (Nasdaq: PSNL). The acquisition will expand Tempus AI’s capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.
Latham & Watkins LLP advised Tempus AI in the transaction with a corporate team led by partners Bradley Faris, Tessa Bernhardt, and Jana Kovich, with associates Ziyad Barghouthy, Matthew Galligan, David Lee, Liem-Lucas Nguyen, Graham Core, and E.B. Nasir. Advice was also provided on capital markets matters by partner Cathy Birkeland, with associates Kenneth Sands, Andrew Rutsky, and Nat Lewis; on compensation and benefits matters by partner Ashley Wagner, with associate Julia Lee; on tax matters by partner Rene de Vera, with associate Jorge Hinzpeter; on labor and employment matters by partner Nineveh Alkhas, with associate Jocelyn Wexler; on intellectual property matters by counsel Arielle Singh, with associate Karen Lee; on intellectual property litigation matters by partner Herman Yue; on data privacy and cybersecurity matters by partner Heather Deixler, with associates Zac Alpert and Ryleigh Chen; on healthcare regulatory matters by partner Betty Pang, with counsel Yanyan Zhou and associate Margaret Rote; on FDA regulatory matters by partner Elizabeth Richards, with associate Evan Miller; on antitrust matters by partners Kelly Fayne, Ian Conner, and Patrick English, with associate Nathaniel Amann; on US securities laws matters by partners Michele Anderson and William Hackett, with associate Sara Almousa; on Nasdaq related matters by partner Gail Neely; and on securities litigation matters by partner Nicholas Siciliano, with associate Matthew Strand.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
